 Connection
Robert Belknap to Humans
This is a "connection" page, showing publications Robert Belknap has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.468 |
|
|
|
-
Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 06; 129:107173.
Score: 0.024
-
Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021 11 02; 73(9):e3459-e3467.
Score: 0.022
-
Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2020 08 22; 71(5):1320-1323.
Score: 0.020
-
Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 02 14; 69(1):1-11.
Score: 0.019
-
Haas MK, Belknap RW. Diagnostic Tests for Latent Tuberculosis Infection. Clin Chest Med. 2019 12; 40(4):829-837.
Score: 0.019
-
Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17; 68(19):439-443.
Score: 0.018
-
Belknap RW. Current Medical Management of Pulmonary Tuberculosis. Thorac Surg Clin. 2019 Feb; 29(1):27-35.
Score: 0.018
-
Haas MK, Belknap RW. Updates in the Treatment of Active and Latent Tuberculosis. Semin Respir Crit Care Med. 2018 Jun; 39(3):297-309.
Score: 0.017
-
Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology. 2018 10; 23(10):893-900.
Score: 0.017
-
Gaensbauer J, Aiona K, Haas M, Reves R, Young J, Belknap R. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic. Pediatr Infect Dis J. 2018 03; 37(3):224-228.
Score: 0.017
-
Belknap R, Reves R. In reply: We and our patients must demand better TB diagnostics. Int J Tuberc Lung Dis. 2017 12 01; 21(12):1316.
Score: 0.016
-
Belknap R, Holland D, Feng PJ, Millet JP, Cayl? JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Mir? JM, Villarino ME, Weiner M, Borisov AS. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 11 21; 167(10):689-697.
Score: 0.016
-
Belknap R, Reves R. Is it time to rethink the role of AFB smears? Int J Tuberc Lung Dis. 2017 07 01; 21(7):720.
Score: 0.016
-
De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R. Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection. J Clin Microbiol. 2017 02; 55(2):391-402.
Score: 0.015
-
Chaulk CP, Belknap R. A public heath 'selfie' for treating tuberculosis? Int J Tuberc Lung Dis. 2016 May; 20(5):571.
Score: 0.015
-
Collins JM, Reves RR, Belknap RW. High Rates of Tuberculosis and Opportunities for Prevention among International Students in the United States. Ann Am Thorac Soc. 2016 Apr; 13(4):522-8.
Score: 0.015
-
Flood J, Scott J, Belknap R. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015 09 17; 373(12):1179.
Score: 0.014
-
Belknap R, Daley CL. Interferon-gamma release assays. Clin Lab Med. 2014 Jun; 34(2):337-49.
Score: 0.013
-
Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, DiCarlo L, Reves R. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013; 8(1):e53373.
Score: 0.012
-
Beieler AM, Jenkins TC, Price CS, Saveli CC, Bruntz M, Belknap RW. Successful limb-sparing treatment strategy for diabetic foot osteomyelitis. J Am Podiatr Med Assoc. 2012 Jul-Aug; 102(4):273-7.
Score: 0.011
-
Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis. 2012 Feb 01; 54(3):e20-3.
Score: 0.011
-
Young H, Swartwood CJ, Jenkins TC, Belknap R. A successful strategy for the use of synergistic intravenous streptomycin in a hemodialysis patient with refractory Enterococcus faecalis bacteremia. J Infect Chemother. 2011 Oct; 17(5):698-9.
Score: 0.010
-
Belknap R, Wall K, Reves R. What can the NHANES data tell us about the tuberculin skin test and the risk for active tuberculosis? Am J Respir Crit Care Med. 2008 Oct 15; 178(8):883-4; author reply 884.
Score: 0.009
-
Gardner EM, Kestler M, Beieler A, Belknap RW. Clostridium butyricum sepsis in an injection drug user with an indwelling central venous catheter. J Med Microbiol. 2008 Feb; 57(Pt 2):236-239.
Score: 0.008
-
Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis. 2005 Sep; 9(9):1057-8.
Score: 0.007
-
Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 09; 20(9):1258-1266.
Score: 0.006
-
Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Cayl? JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 06 16; 76(12):2090-2097.
Score: 0.006
-
Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790.
Score: 0.006
-
Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-? release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Jul; 28(7):1023.e1-1023.e7.
Score: 0.006
-
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875.
Score: 0.005
-
Pettit AC, Stout JE, Belknap R, Benson CA, S?raphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021 10 05; 73(7):e2278-e2284.
Score: 0.005
-
Feng PJ, Wu Y, Ho CS, Chinna L, Whelen AC, Largen A, Brostrom R, Reves R, Belknap R, Cattamanchi A, Banaei N. Impact of T-Cell Xtend on T-SPOT.TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. J Clin Microbiol. 2021 04 20; 59(5).
Score: 0.005
-
Gaensbauer J, Young J, Harasaki C, Aiona K, Belknap R, Haas MK. Interferon-Gamma Release Assay Testing in Children Younger Than 2 Years in a US-Based Health System. Pediatr Infect Dis J. 2020 09; 39(9):803-807.
Score: 0.005
-
Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65.
Score: 0.005
-
Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 07 15; 202(2):305-306.
Score: 0.005
-
Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020 03 01; 201(5):598-605.
Score: 0.005
-
Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection. J Clin Microbiol. 2019 11; 57(11).
Score: 0.005
-
Gaensbauer J, Gonzales B, Belknap R, Wilson ML, O'Connor ME. Interferon-Gamma Release Assay-Based Screening for Pediatric Latent Tuberculosis Infection in an Urban Primary Care Network. J Pediatr. 2018 09; 200:202-209.
Score: 0.004
-
Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018 05; 15(5):570-580.
Score: 0.004
-
Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, Parker M, Garrett DO, Daley CL. Interferon-? release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014 Jan 01; 189(1):77-87.
Score: 0.003
-
Saveli CC, Morgan SJ, Belknap RW, Ross E, Stahel PF, Chaus GW, Hak DJ, Biffl WL, Knepper B, Price CS. Prophylactic antibiotics in open fractures: a pilot randomized clinical safety study. J Orthop Trauma. 2013 Oct; 27(10):552-7.
Score: 0.003
-
Walter ND, Strong M, Belknap R, Ordway DJ, Daley CL, Chan ED. Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology. 2012 Jul; 17(5):772-91.
Score: 0.003
-
Saveli CC, Belknap RW, Morgan SJ, Price CS. The role of prophylactic antibiotics in open fractures in an era of community-acquired methicillin-resistant Staphylococcus aureus. Orthopedics. 2011 Aug; 34(8):611-6; quiz 617.
Score: 0.003
-
Spencer JS, Kim HJ, Wheat WH, Chatterjee D, Balagon MV, Cellona RV, Tan EV, Gelber R, Saunderson P, Duthie MS, Reece ST, Burman W, Belknap R, Mac Kenzie WR, Geluk A, Oskam L, Dockrell HM, Brennan PJ. Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. Clin Vaccine Immunol. 2011 Feb; 18(2):260-7.
Score: 0.003
-
Koeppe J, Belknap R, Bessesen M. Mycobacterium avium complex peritonitis in the setting of cirrhosis: case report and review of the literature. Scand J Infect Dis. 2004; 36(8):615-7.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|